Jan-04-21 08:30AM |
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development OfficerGlobeNewswire |
Dec-22-20 07:31AM |
Cassava Sciences' (SAVA) Shares March Higher, Can It Continue?Zacks |
Dec-07-20 08:19AM |
Is SAVA A Good Stock To Buy Now?Insider Monkey |
Nov-27-20 08:30AM |
USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’GlobeNewswire |
Nov-19-20 10:08AM |
Pacira (PCRX) Gets European Commission Approval for ExparelZacks |
Nov-18-20 09:36AM |
3 Best Biotech Stocks to Buy in NovemberMotley Fool |
Nov-16-20 10:06AM |
Aerie (AERI) Gets Positive CHMP Opinion for Roclanda in EUZacks |
Nov-13-20 09:42AM |
Zoetis (ZTS) Librela Gets Marketing Authorization in EuropeZacks |
09:08AM |
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common StockGlobeNewswire |
Nov-13-20 08:07AM |
Why Cassava Sciences Stock Is Retreating TodayMotley Fool |
Nov-12-20 04:48AM |
Cassava Sciences Announces Proposed Public Offering of Common StockGlobeNewswire |
Nov-09-20 08:15AM |
Cassava Sciences Reports Third Quarter 2020 Financial ResultsGlobeNewswire |
Nov-04-20 08:15AM |
Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s DiseaseGlobeNewswire |
Oct-26-20 09:19AM |
What's in the Cards for Cassava (SAVA) This Earnings Season?Zacks |
Oct-23-20 10:15AM |
Why Cassava Sciences Is Bolting Higher TodayMotley Fool |
Oct-12-20 03:29AM |
We're Not Worried About Cassava Sciences' (NASDAQ:SAVA) Cash BurnSimply Wall St. |
Oct-07-20 09:35AM |
Why Cassava Sciences Stock Crushed It in SeptemberMotley Fool |
07:05AM |
Moving Average Crossover Alert: Cassava SciencesZacks |
Sep-30-20 08:30AM |
Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020GlobeNewswire |
07:55AM |
4 Small Drug Stocks to Look Out For Amid Coronavirus UncertaintyZacks |
Sep-28-20 07:44AM |
Cassava Sciences (SAVA) Stock Is up 255% This Month. How Much Higher Can It Go?TipRanks |
07:38AM |
Cassava Sciences' Shares March Higher, Can It Continue?Zacks |
Sep-27-20 08:09AM |
Is Cassava Sciences Stock a Buy?Motley Fool |
Sep-22-20 10:04AM |
Why Cassava Sciences Stock Is Bolting Higher TodayMotley Fool |
Sep-21-20 01:34AM |
Trading My First Red Week After Six Months Of GreenBenzinga |
Sep-20-20 06:53AM |
Does Cassava Sciences Have the Alzheimer's Disease Drug We've Been Waiting For?Motley Fool |
Sep-16-20 02:03AM |
This Biotech Stock Moves One Step Closer to an Alzheimer’s Drug; Analyst Says ‘Buy’TipRanks |
Sep-14-20 12:44PM |
Cassava Sciences rockets on heavy volume after Alzheimer's drug trial results prompts analyst upgradeMarketWatch |
07:15AM |
Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s DiseaseGlobeNewswire |
Sep-11-20 04:01AM |
Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ETGlobeNewswire |
Sep-09-20 08:15AM |
Cassava Sciences to Present at H.C. Wainwright’s 22nd Annual Global Investment ConferenceGlobeNewswire |
Sep-03-20 08:15AM |
Cassava Sciences Announces New Patent GrantGlobeNewswire |
Aug-24-20 08:15AM |
Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name ‘sumifilam’ by USANGlobeNewswire |
Aug-12-20 08:15AM |
Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business ReviewGlobeNewswire |
Jul-14-20 08:44AM |
Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%Zacks |
Jul-09-20 04:01AM |
Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific ConferenceGlobeNewswire |
Jun-16-20 08:15AM |
Cassava Sciences Added to Russell Indexes and Provides Phase 2b Study UpdateGlobeNewswire |
Jun-10-20 04:33AM |
Hedge Funds Cautiously Watching Cassava Sciences, Inc. (SAVA)Insider Monkey |
Jun-03-20 08:15AM |
Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2b Study of PTI-125GlobeNewswire |
May-19-20 07:57AM |
Cassava Sciences (SAVA): Let’s Shed Some Light on That CrashTipRanks |
09:46AM |
Cassava Sciences (SAVA) in Focus: Stock Moves 8.5% HigherZacks |
May-15-20 02:05AM |
Cassava Sciences Alzheimer's Drug Candidate Misses Trial EndpointTheStreet.com |
11:31AM |
Cassava stock falls on failed Alzheimer's studyMarketWatch |
May-15-20 08:15AM |
Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer’s Disease Does Not Meet Primary EndpointGlobeNewswire |
May-06-20 08:48AM |
Add Value to Your Portfolio With 5 High Earnings Yield PicksZacks |
08:15AM |
Cassava Sciences Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswire |
Apr-24-20 10:03AM |
Company News for Apr 24, 2020Zacks |
Apr-23-20 08:15AM |
Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of HealthGlobeNewswire |
Apr-13-20 01:25AM |
We're Excited To See How Cassava Sciences (NASDAQ:SAVA) Uses Its Cash Hoard To GrowSimply Wall St. |
Mar-26-20 08:15AM |
Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020GlobeNewswire |